Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 236
Tipo Título / Nombre Autor(es) Año
A novel in vitro method to quantify the pharmacology activity of bispecific antibodies in hematological samples Primo D, Hernández P, Ghia P, Serna J de la, Ribera JM, Vives S, Bergua JM, Pérez de Oteyza J, Serrano J, Gorrochategui J, Vicente ML, Gómez C, Martinelli G, Simonetti G, Ranghetti P, Scarfo L, Martínez-Cuadron D, Montesinos P, Martínez J, Ballesteros J 2017
Validation of precision medicine test for acute myeloid leukemia in an observational clinial trial Montesinos P, Ballesteros J, Martínez Cuadron D, Martínez López J, Errano J, Pérez de Oteyza J, Bergua J, Tormo M, [et.al] 2017
The Impact of the Administration Schedule and Mutational Profile on Outcomes of Patients with Relapsed and Refractory Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Large, International, Multi-Center Analysis Stahl M, Deveaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Podoltsev NA, Fathi AT, Komrokji RS, Navneet S, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Brunner AM, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kon Kin T, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore S, Zeidan AM 2017
Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)— Transplant Outcomes Post HMA Therapy in a Large International Patient Cohort Stahl M, Deveaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Navneet S, Majahail N, Podoltsev NA, Fathi AT, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Brunner AM, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kon Kin T, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore S, Zeidan AM 2017
Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) Deveaux M, Stahl M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow MR, Fathi AT, Perreault S, Kon Kin T, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore S, Zeidan AM 2017
Is the Outcome of Patients with High Risk T-Cell Acute Lymphoblastic Leukemia Improving in the Era of Pediatric—Inspired Protocols? a Comparison of 2 Consecutive Pethema Trials Barba Pere, Morgades Mireia, Montesinos Pau, Gil Cristina, Fox María Laura, Ciudad Juana, Moreno MJ, González-Campos J, Genesca E, Martínez-Carballeira D, Martino R, Vives S, Guardia R, Mercadal S, Artola MT, Cladera A, Tormo M, Esteve J, Bergua J, Vall-Llovera F, Ribera J, Martínez Sánchez, Amigo ML, Bermudez A, Calbacho M, Hernández Rivas JM, Feliu E, Ribera JM, 2017
Bispecific Antibodies on Hematological Malignancies: A Novel Mechanism of Action That May Contribute to Therapeutic Efficacy Primo D, Hernández P, Serna J de la, Ribera JM, Vives S, Bergua J, Pérez de Oteyza J, Serrano J, Gorrochategui J, Vicente ML, Martínez-Cuadron D, Montesinos P, Martínez López J, Ballesteros J 2017
Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Brunet S, Bergua J, Tormo M, García-Boyero R, Sarrà J, Del Potro E, Grande C, Barba P, Bernal T, Amigo ML, Grau J, Cervera J, Feliu E, PETHEMA Group, Spanish Society of Hematology 2017
Immunosenescence: limitations of natural killer cell-based cancer immunotherapy Tarazona R, Sánchez-Correa B, Casas-Avilés I, Campos C, Pera A, Morgado S, López-Sejas N, Hassouneh F, Bergua JM, Arcos MJ, Bañas H, Casado JG, Durán E, Labella F, Solana R 2017
In Vitro Culture with Interleukin-15 Leads to Expression of Activating Receptors and Recovery of Natural Killer Cell Function in Acute Myeloid Leukemia Patients Sánchez-Correa B, Bergua JM, Pera A, Campos C, Arcos MJ, Bañas H, Duran E, Solana R, Tarazona R 2017